In recent years, CSN6 has been reported to exhibit upregulated expression and play vital roles in tumorigenesis and progression in lung cancer, glioblastoma, colorectal cancer, breast cancer, thyroid papillary cancer, cervical cancer, and pancreatic cancer7,11,13,20–25, suggesting that CSN6 may be a possible prognostic marker and therapeutic target in a variety of cancers. The gene discussed is COPS6; the disease is lung carcinoma.